Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The CD4 binding site on HIV's envelope glycoprotein precursor (gp160)—specifically localized within its mature surface subunit, gp120—is indispensable for virus attachment to host immune cells via direct interaction with their CD4 receptors. Its structural conservation makes it both an Achilles’ heel exploited by neutralizing antibodies/vaccine strategies and a focal point in understanding mechanisms underlying viral entry/fusion dynamics.
Inhibition of viral attachment by blocking the interaction between gp120 and the CD4 receptor on host cells
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD4 Binding Site on Envelope Glycoprotein gp160 (HIV) (CD4 Binding Site (gp160)).